Modulation of interleukin-6 expression in Hodgkin and Reed-Sternberg cells by Epstein-Barr virus

Journal of Pathology

Volumn 182, Issue 3, 1997, Pages 299-306

  Herbst, Hermann ^a,b   Samol, Jens ^a   Foss, Hans Dieter ^a   Raff, Thorsten ^a   Niedobitek, Gerald ^c  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Epstein Barr virus; Hodgkin and Reed Sternberg cells; Hodgkin's disease; Interleukin 6; Latent membrane protein; LMP1

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REED STERNBERG CELL;

CASE-CONTROL STUDIES; GENE EXPRESSION; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; IN SITU HYBRIDIZATION; INTERLEUKIN-6; REED-STERNBERG CELLS; VIRAL MATRIX PROTEINS;

EID: 0030742483     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199707)182:3<299::AID-PATH856>3.0.CO;2-8     Document Type: Article

References (41)

1. Herbst, H, Dallenbach F, Hummel M, et al. Epstein-Barr virus latent membrane antigen expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA 1991; 88: 4766-4770.
2. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991; 337: 320-322.
3. Herbst H, Niedobitek G. Epstein -Barr virus in Hodgkin's disease. EBV Rep 1994; 1: 31-35.
4. Henderson S, Rowe M, Croom-Carter D, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein I protects infected B cells from programmed cell death. Cell 1991; 65: 1107-1115.
5. Gruss HJ, Hermann F, Drexler HG. Hodgkin's disease: a cytokine-producing tumor-a review. Crit Rev Oncogenesis 1994; 5: 473-538.
6. Tabibzadeh SS, Poubouridis D, May LT, Sehgal B. Interleukin-6 immunoreactivity in human tumors. Am J Pathol 1989; 135: 427-433.
7. Jücker M, Abts H, Li W, et al. Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease. Blood 1991; 77: 2413-2418.
8. Foss HD, Herbst H, Oelmann E, et al. Lymphotoxin, tumor necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases. Br J Haematol 1993; 84: 627-635.
9. Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1-10.
10. Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol Today 1990; 11: 443-449.
11. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83-85.
12. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73: 517-526.
13. Tosato G, Tanner J, Jones KD, Revel M, Pike SE. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol 1990; 64: 3033-3041.
14. Foss HD, Herbst H, Hummel M, et al. Patterns of cytokine gene expression in infectious mononucleosis. Blood 1994; 83: 707-712.
15. Scala G, Quinto I, Ruocco MR, et al. Expression of an exogenous interleukin 6 gene in human Epstein-Barr virus B cells confers growth advantage and in vivo tumorigenicity. J Exp Med 1990; 172: 61-68.
16. Yamasaki K, Taga T, Hirata Y, et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN β2) receptor. Science 1988; 241: 825-828.
17. Taga T, Hibi M, Hirata Y, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989; 58: 573-581.
18. Herbst H, Steinbrecher E, Niedobitek G, et al. Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin's disease. Blood 1992; 80: 484-491.
19. Stein H, Gatter K, Asbahr H, Mason DY. Use of freeze-dried paraffin-embedded sections for immunohistologic staining with monoclonal antibodies. Lab Invest 1985; 52: 676-683.
20. Kikutani H, Kishimoto T. The cytokine receptors: section report. In: Schlossman SF, Boumsell L, Gilks W, et al., eds. Leukocyte Typing V: White Cell Differentiation Antigens. Oxford: Oxford University Press, 1995: 1855-1864.
21. Sutherland GR, Baker E, Callen DF, at al. Interleukin-4 is at 5q31 and interleukin-6 is at 7p15. Hum Genet 1988; 79: 335-337.
22. Herbst H, Foss HD, Samol J, et al. Frequent expression of interleukin-10 in Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 1996; 87: 2918-2929.
23. Jat P, Arrand JR. In vitro transcription of two Epstein-Barr virus specified small RNA molecules. Nucleic Acids Res 1982; 10: 3407-3425.
24. Williamson DJ. Specificity of riboprobes for intracellular RNA in hybridisation histochemistry. J Histochem Cytochem 1988; 26: 811-813.
25. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res 1993; 53: 2118-2122.
26. Gause A, Scholz R, Klein S, et al. Increased levels of circulating interleukin-6 in patients with Hodgkin's disease. Hematol Oncol 1991; 9: 307-313.
27. Miyashita EM, Yang B, Lam KM, Crawford DH, Thorley-Lawson DA. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 1995; 80: 593-601.
28. Rowe M, Rowe DT, Gregory CD, et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 1987; 6: 2743-2751.
29. Fahraeus R, Fu HL, Ernberg I, et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988; 42: 329-338.
30. Hamilton-Dutoit SJ, Rea D, Raphael M, et al. Epstein Barr virus latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am J Pathol 1993; 143: 1072-1085.
31. Rochford R, Dawson CW, Mosier DE, Young LS. Epstein Barr virus latent proteins activated cytokine gene expression in epithelial cells. In: Epstein-Barr Virus and Associated Diseases. Cold Spring Harbor Meeting on Cancer Cells 1994 Book of Abstracts. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1994; 70.
32. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signalling proteins for the tumor necrosis factor receptor family. Cell 1995; 80: 389-399.
33. Rowe M, Peng-Pilon M, Huen DS, et al. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP-1: a B-cell-specific response that is delayed relative to NF-κB activation and to induction of cell surface markers. J Virol 1994; 68: 5602-5612.
34. Mori N, Shirakawa F, Shimizu F, et al. Transcriptional regulation of the human interleukin-6 gene promoter in human T-cell leukemia virus type I-infected T-cell lines: evidence for the involvement of NF-κB. Blood 1994; 84: 2904-2911.
35. Stein H, Mason DY, Gerdes J, et al. The expression of Hodgkin's disease-associated antigen Ki-1 in reactive and neoplastic lymphoid tissue. Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 849-858.
36. Carbone A, Gloghini A, Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995; 85: 780-789.
37. Munro JM, Freedman AS, Aster JC, et al. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 1994; 83: 793-798.
38. Rothenberger S, Mitchell T, Bachmann E, McQuain C, Quesenberry PJ, Knecht H. Maximal stimulation of NF-κB activity in LMP1 deletion variants from patients with EBV-associated relapsing Hodgkin's disease. Blood 1995; 86: 741a.
39. Mackiewicz A, Wizuerowicz M, Roeb E, et al. Soluble interleukin 6 receptor is biologically active. Cytokine 1995; 7: 142-149.
40. Herbst H, Raff T, Stein H. Phenotypic modulation of Hodgkin and Reed-Sternberg cells by Epstein-Barr virus. J Pathol 1996; 179: 54-59.
41. Vestlev PM, Pallesen G, Sandvej K, Hamilton-Dutoit SJ, Bendtzen SM. Prognosis of Hodgkin's disease is not influenced by Epstein-Barr virus latent membrane protein. Int J Cancer 1992; 50: 670-671.